Effects of Energy Drinks on Cardiovascular Endpoints

Part of paid clinical trials in Stockton, California.

Sponsor
University of the Pacific
Study ID
NCT07212803
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers
  • Safety After Oral Intake

Eligibility Criteria

Sex
ALL
Age
18 Years - 40 Years
Healthy Volunteers
Accepted

Interventions

  • Energy Drink A + Placebo Capsule — DIETARY_SUPPLEMENT
    1000 mL caffeine- and taurine-containing commercially available beverage (Formula A) consumed with placebo capsule
  • Placebo Drink + Moxifloxacin Capsule — DRUG
    Placebo drink with 400 mg moxifloxacin capsule
  • Placebo Drink + Caffeine Capsule — DIETARY_SUPPLEMENT
    Placebo drink with 320 mg caffeine capsule
  • Placebo Drink + Placebo Capsule — OTHER
    Placebo drink with placebo capsule
  • Energy Drink B — DIETARY_SUPPLEMENT
    568 mL caffeine- and taurine-containing commercially available beverage (Formula B)
  • Control Product + Taurine — DIETARY_SUPPLEMENT
    Control product with 4000 mg taurine powder
  • Control Product + Caffeine + Taurine — DIETARY_SUPPLEMENT
    Control product with 320 mg caffeine + 4000 mg taurine powder
  • Lower Dose Energy Drink A — DIETARY_SUPPLEMENT
    591 mL caffeine- and taurine-containing commercially available beverage (Formula A)

Study Details

This is a clinical trial looking at the impact of energy drinks on heart related parameters. The study will enroll 3 participants who will be exposed to 8 different interventions.

Key Dates

Start date
Nov 1, 2025
Status verified
Nov 2025
Primary completion
Mar 31, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
3 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER

Arms

  • Experimental: Phase A: Energy Drink A + Placebo
    Energy Drink A (320 mg caffeine) consumed with placebo capsule
  • Active Comparator: Phase A: Placebo Drink + Moxifloxacin
    Placebo drink with 400 mg moxifloxacin capsule
  • Active Comparator: Phase A: Placebo Drink + Caffeine
    Placebo drink with 320 mg caffeine capsule
  • Placebo Comparator: Phase A: Placebo Drink + Placebo Capsule
    Placebo drink with Placebo capsule
  • Experimental: Phase B: Energy Drink B
    Energy Drink B (320 mg caffeine)
  • Experimental: Phase B: Control + Taurine
    Control product with 4000 mg taurine powder
  • Experimental: Phase B: Control + Caffeine + Taurine
    Control product with 320 mg caffeine + 4000 mg taurine powder
  • Experimental: Phase B: Lower Dose Energy Drink A
    Energy Drink A (189 mg caffeine)

Primary Outcome Measure

Change from Baseline in Corrected QT Interval (QTc) in Milliseconds (ms) [ Time Frame: Baseline, 30, 60, 90, 120, 150, 180, and 240 minutes post-intervention ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of the PacificStocktonCalifornia95211
Quy Phan, PharmD
[email protected]
209-946-7754

Find similar trials in Stockton, CA

By research site
University of the Pacific· Stockton, CA

Related Studies